Ivan Pena, MD
Interventional Cardiology · Louisville, KYNPI 1770978587
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,063 of the $19,809 with a category attached, or 65.9%. 35 manufacturers reported payments, led by Penumbra, Inc. at 34.1% of the total.
Across 326 payments — averaging $60.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$7K
- Abbott$3K
- Medtronic$2K
- Teleflex LLC$2K
- Boston Scientific$1K
- Pfizer$902
- plus $4K from 29 others
What the payments were for
- Travel & lodging$5,97030%
- Food & beverage$13,06366%
- Education$7014%
- Gifts$750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 29 | $6,765 |
| Abbott | 21 | $2,897 |
| Medtronic | 26 | $2,418 |
| Teleflex LLC | 28 | $1,658 |
| Boston Scientific | 28 | $1,183 |
| Pfizer | 54 | $902 |
| E.r. Squibb & Sons, L.L.C. | 28 | $616 |
| AstraZeneca | 10 | $486 |
| Shockwave Medical, Inc | 7 | $460 |
| Novartis | 29 | $444 |
| Johnson & Johnson | 14 | $264 |
| Abiomed | 6 | $217 |
| Terumo Medical Corporation | 4 | $208 |
| Philips North America LLC | 2 | $144 |
| Asahi Intecc USA, Inc. | 2 | $142 |
| Inari Medical, Inc. | 2 | $137 |
| Merck | 8 | $133 |
| Astellas Pharma US Inc | 1 | $99 |
| Lexicon Pharmaceuticals, Inc. | 2 | $98 |
| Amgen | 4 | $76 |
| Chiesi USA, Inc. | 1 | $75 |
| Reflow Medical Inc | 2 | $63 |
| Boehringer Ingelheim | 3 | $53 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Edwards Lifesciences | 1 | $34 |
| Scpharmaceuticals Inc. | 1 | $28 |
| Stryker | 2 | $28 |
| Cardiovascular Systems Inc. | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Atricure, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$6,432
- OPTIS$1,485
- RESOLUTE ONYX$1,243
- Ensite Cardiac Mapping System$457
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$317
- TRAPLINER$311
- GUIDELINER$293
- AVVIGO Guidance System$278
- BRILINTA$251
- FLOWTRIEVER CATHETER, S$239
- Orsiro Mission$223
- GENERAL - STRUCTURAL HEART$173
- Diamondback Coronary$154
- TURNPIKE$154
- DRAGONFLY OPSTAR$148
- Simulus$146
- Resolute$144
- WATCHMAN Access System$143
- (5027) Intact Vascular Und$129
- METACROSS OTW$127
How this compares
$19,809 in reported general payments places this provider in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $95,482 |
| JardianceEmpagliflozin | 40 | $41,993 |
| EntrestoSacubitril/Valsartan | 45 | $35,665 |
| XareltoRivaroxaban | 25 | $35,652 |
| BrilintaTicagrelor | 30 | $25,257 |
| Repatha SureclickEvolocumab | 22 | $19,870 |
| FarxigaDapagliflozin Propanediol | 16 | $11,619 |
| Praluent PenAlirocumab | 12 | $5,656 |
| Ranolazine ErRanolazine | 26 | $4,051 |
| Metoprolol Succinate | 278 | $3,132 |
| ClopidogrelClopidogrel Bisulfate | 232 | $2,222 |
| Atorvastatin Calcium | 185 | $1,486 |
| Losartan Potassium | 129 | $1,187 |
| Carvedilol | 157 | $907 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 63 | $781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $902 | $95,482106 claims |
| Boehringer IngelheimJardiance | $53 | $41,99340 claims |
| AstraZenecaBrilinta, Farxiga | $486 | $36,87646 claims |
| NovartisEntresto | $444 | $35,66545 claims |
| Johnson & JohnsonXarelto | $264 | $35,65225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Louisville
- Daniel StewartLouisville$290K
- Daniel RothschildLouisville$154K
- Naresh SolankhiLouisville$132K
- Ravi SharmaLouisville$86K
- Christopher SemderLouisville$50K
- Sadip PantLouisville$43K
- Michael FlahertyLouisville$42K
- Prafull RahejaLouisville$27K
- Faraaz RahmanLouisville$22K
- Hussayn AlrayesLouisville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.